Alkermes has shown more of the data that persuaded it to throw money at its narcolepsy program. The phase 1b readout suggests Alkermes’ ALKS 2680 can hold its own against Takeda’s rival prospect ...

DUBLIN, June 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 ...

Alkermes (NASDAQ:ALKS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS – Research Report), Eledon Pharmaceuticals (ELDN – Research Report) and Legend Biotech ...

Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th ...

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.

A month has gone by since the last earnings report for Alkermes (ALKS). Shares have lost about 2.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading ...

Alkermes just unveiled an announcement. Alkermes plc shareholders, during their 2024 Annual Meeting, approved key amendments to the company’s stock plan, including a substantial ...

DUBLIN, May 28, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th annual meeting of the Associated ...

Alkermes ALKS has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings ...

Details of Alkermes' presentations at SLEEP 2024 are as follows: "Safety and Pharmacodynamic Effects of the Orexin 2 Receptor Agonist ALKS 2680 in Patients with Narcolepsy Type 1: A First-in-Human ...